Kashish Tandon

1 day ago | gurutrade.com | Rishika Sadam |Kashish Tandon |Eileen Soreng

May 13 (Reuters) - Cipla, India's third-biggest drugmaker by sales, reported a fourth-quarter profit that beat estimates on Tuesday, helped by strong demand for its drugs used to treat chronic conditions, especially respiratory illnesses. The company's consolidated net profit came in at 12.22 billion rupees ($143.5 million) in the January-March period. Analysts, on average, expected 10.24 billion rupees, per data compiled by LSEG. Total revenue increased 9.2% to 67.3 billion rupees.

1 day ago | marketscreener.com | Rishika Sadam |Kashish Tandon

(Reuters) -Cipla, India's third-largest drugmaker by sales, posted fourth-quarter profit above estimates on Tuesday and said it will focus on new drug launches in the key domestic and U.S. markets to drive growth in the coming years. In India, its largest market by sales, Cipla plans to launch innovative drugs and expand its portfolio in diabetes, neurology, and cardiac therapies. The company said weight-loss drugs will also be a key growth driver in India and emerging markets.

2 days ago | jp.reuters.com | Rishika Sadam |Kashish Tandon

[ハイデラバード ９日 ロイター] - インドのジェネリック医薬品（後発薬）メーカー、ドクター・レディーズ・ラボラトリーズ(REDY.NS), opens new tabが９日発表した２０２５年第４・四半期（１─３月）決算は純利益が１５９億３０００万ルピー（約１億８７００万ドル）となり、ＬＳＥＧがまとめたアナリスト予想平均の１４９億１０００万ルピーを上回った。がんおよび他の慢性疾患治療薬分野で新薬を投入したことが追い風となった。また、トランプ米政権が追加関税を課す可能性に備え、米国の生産拠点を拡大する方針を示した。 総売上高は前年同期比２０％増の８２１億１０００万ルピーだった。 最大市場である北米の売上高は９％増の３５５億９０００万ルピー。欧州市場の売上高は１２７億６０００万ルピーと２倍超増えた。昨年、消費者向けヘルスケア事業を手がける英ヘイリオン(HLN.L), opens new tabから買収したニコチン代替療法（ＮＲＴ）の需要好調が売り上げを押し上げた。...

2 days ago | gurutrade.com | Kashish Tandon |Nivedita Bhattacharjee |Mrigank Dhaniwala

May 12 (Reuters) - Indian pharma stocks fell 1.6% on Monday, bucking broader market gains, after U.S. President Trump said he would cut drug prices by 30%–80% to match other wealthy nations. Trump said he would sign an executive order on Monday to pursue "most favored nation" pricing. The U.S. currently pays nearly three times more for many prescription drugs, though Trump offered no implementation details.

5 days ago | marketscreener.com | Rishika Sadam |Kashish Tandon

HYDERABAD (Reuters) -India's Dr Reddy's Laboratories, one of country's largest generic drugmakers, said that it is open to expanding its manufacturing footprint in the key U.S. market as tariff threat looms. "We are more than open to work in the United States, to make in the United States when the opportunity comes," CEO Erez Israeli said in a press call on Friday. "We want to invest (in the U.S.)...